Results 131 to 140 of about 53,515 (238)

Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes

open access: yes, 2018
Peng Chen,1,* Fuchao Chen,2,* Benhong Zhou1,3 1Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People’s Republic of China; 2Department of Pharmacy, Dongfeng Hospital, Hubei University of Medicine, Shiyan, Hubei ...
Chen P, Chen FC, Zhou BH
core  

Complete Regression of bilateral Choroidal Metastases secondary to a Cutaneous Melanoma under Immunotherapy

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela   +6 more
wiley   +1 more source

The role of extracellular vesicles in cell–cell crosstalk in cardiotoxicity

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Administration of a pharmacological agent can result in off‐target cardiotoxicity which can be driven by cell–cell crosstalk between healthy and dysfunctional cardiac cells. Extracellular vesicles (EVs) are lipid bilayer structures that can move biological cargo between cells, facilitating cell–cell crosstalk.
Gabriella Bachynskyj‐Bilas   +5 more
wiley   +1 more source

Emerging options for the treatment of melanoma – focus on ipilimumab

open access: yesImmunoTargets and Therapy, 2014
Claire Roddie, Karl S Peggs UCL Cancer Institute, Department of Hematology, London, UK Abstract: Ipilimumab is a fully human immunoglobulin subclass G1 anticytotoxic-T-lymphocyte-antigen-4 monoclonal antibody.
Roddie C, Peggs KS
doaj  

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy: Clinical Studies

open access: yes
BACKGROUND: Ipilimumab+nivolumab (IPINIVO) can induce durable responses in advanced melanoma, but many patients experience progression at some point. It is currently unknown to what extent these patients benefit from IPINIVO rechallenge.
van der Veldt, A A M   +27 more
core  

Unraveling the Plasma Extracellular Vesicles Proteome: Predictors of Resistance in Immunotherapy of Advanced Melanoma

open access: yesInternational Journal of Cancer, Volume 159, Issue 11, Page 2824-2834, 1 December 2026.
ABSTRACT Despite substantial clinical benefit from immune checkpoint inhibitors (ICI), advanced melanoma remains challenging due to frequent treatment resistance. Resistance may be intrinsic (primary) or emerge over time (secondary). Biomarkers predicting distinct resistance phenotypes before therapy are lacking.
Julian Kött   +17 more
wiley   +1 more source

The single-center safety observation of ipilimumab combined with chemotherapy in the treatment of advanced squamous cell carcinoma

open access: yesZhongguo aizheng zazhi, 2017
Background and purpose: Checkpiont targeted immunotherapy in the field of solid tumor therapy has huge potential, triggering a boom in the study of immune targeted drugs.
胡章国, 周 严, 刘显勋
doaj  

Immune effector cell‐associated neurotoxicity syndrome (ICANS) during tebentafusp in metastatic uveal melanoma

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Laura Schreieder   +7 more
wiley   +1 more source

The Place of Therapeutic Apheresis in Severe Immune‐Related Adverse Events: A Scoping Review of Literature

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 6, December 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the management of patients with cancer. However, they can induce breakdowns in immunologic tolerance, leading to autoimmune diseases, or immune related adverse events (irAEs). These irAEs can sometimes be life threatening, requiring aggressive management, such as immunosuppressant (IS) or
C. Vuillet   +36 more
wiley   +1 more source

Immune checkpoint inhibitor‐induced colitis or infectious mimic? Considering Paeniclostridium sordellii

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Thomas Breakell   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy